buy digital currency snippets

Shanghai builds a merger and reorganization head company, and Ning Wang magnifies the move. The bull market still needs to be believed.Contemporary Amperex Technology Co., Limited announced that the company plans to pay dividends with 15% of the net profit in the first three quarters of 2024, that is, 5.4 billion yuan as the total distribution, and distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares. In addition, Contemporary Amperex Technology Co., Limited and Stellantis plan to jointly set up a joint venture company in Spain, with each party holding 50% of the shares. The estimated total investment of the battery factory is 4.038 billion euros.

Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.Many of them announced their reduction in the evening, except for the 11-board Yiming food, others also included.Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;

In addition, it is planned to distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares, with a total dividend of 4.5 billion yuan. In April this year, Ningde has paid dividends of 22 billion yuan, and this time it totaled 27.4 billion yuan. According to the current market value of 11,900, the corresponding dividend yield is 2.3%! It's really not low.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.